Yderligere analyse viste, at Trevaclyn (2. 000 mg/ 40 mg) administreret sammen med simvastatin, i sammenligning med simvastatin alene, øgede apo- A- I signifikant (henholdsvis 8, 6%, 2, 3%) og reducerede Lp( a) signifikant (henholdsvis - 19, 8%, 0, 0%).
Further analysis showed Trevaclyn (2000 mg/ 40 mg) co-administered with simvastatin when compared with simvastatin alone significantly increased apo A-I (8.6%, 2.3% respectively) and significantly decreased Lp(a) (-19.8%, 0.0% respectively).